AstraZeneca today announced positive top-line results from the Phase III
PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and
PINNACLE 2) to investigate the potential of PT003 to improve lung function in
patients with Chronic Obstructive Pulmonary Disease (COPD).

PT003 is a twice-daily fixed-dose combination of glycopyrronium, a long-acting
muscarinic antagonist (LAMA) and formoterol fumarate, a long-acting beta-2
agonist (LABA). PT003 is the first LAMA/LABA combination to be delivered in a
pressurised metered dose inhaler (pMDI) using the unique porous particle co
-suspension technology developed by Pearl Therapeutics, which was acquired by
AstraZeneca in 2013. The development programme also included assessment of the
individual components of PT003 - glycopyrronium pMDI (PT001) and formoterol
fumarate (PT005) pMDI. The successful completion of the PINNACLE studies marks
the first Phase III outcomes from a series of pipeline candidates under
development by AstraZeneca using Pearl's novel technology.

In both the PINNACLE 1 and PINNACLE 2 studies, the primary objective was to
assess benefits on lung function as measured by trough forced expiratory volume
in one second (FEV1). PT003 demonstrated statistically significant improvements
in trough FEV1 versus PT001, PT005 and placebo. Both PT001 and PT005 also
demonstrated statistically significant improvements in trough FEV1 compared to

In PINNACLE 1 and PINNACLE 2, the most common adverse events across all
treatment arms, including placebo, were nasopharyngitis, upper respiratory tract
infection, and dyspnea. The incidence of adverse events was generally similar
across all treatment groups. The Phase III programme also included a 28-week
extension study, PINNACLE 3, the safety information from which is not yet

Briggs Morrison, Executive Vice President, Global Medicines Development and
Chief Medical Officer at AstraZeneca, said: "These positive top-line results
demonstrate the potential of PT003 as a novel treatment for patients suffering
with the debilitating and chronic symptoms of COPD. The ability to deliver a
unique LAMA/LABA formulation in a single pressurised metered dose device is
important for helping some 30% of patients around the world who use an aerosol
inhaler. Today's results are also encouraging for the development of our
investigative triple-drug combination of LAMA/LABA and inhaled corticosteroids."

AstraZeneca plans to file global regulatory applications for PT003 commencing in
2015. Data from the PINNACLE 1, 2, and 3 Phase III studies will be presented at
a scientific meeting later in the year.


The PINNACLE Phase III Pivotal Programme

The PT003 Phase III pivotal programme consists of PINNACLE 1, PINNACLE 2, and an
extension study, PINNACLE 3. Overall the Phase III pivotal programme enrolled
over 3,700 patients with COPD at over 275 study sites.

PINNACLE 1 and PINNACLE 2 were Phase III randomised, double-blind, multi-centre,
placebo-controlled studies. In both studies, the efficacy and safety of PT003
administered twice daily via pressurised metered dose inhaler (pMDI) was
compared to its monotherapy components: glycopyrronium (PT001), a LAMA, and
formoterol fumarate (PT005), a LABA, and placebo. PT001 and PT005 were also
compared to placebo. In PINNACLE 1, open-label tiotropium was included as an
active control. Both studies were conducted over 24 weeks in subjects with COPD.

The primary objective of both studies was improvement in lung function as
assessed by trough forced expiratory volume in one second (FEV1).

PINNACLE 3 was a multi-centre, randomised, double-blind, parallel-group, chronic
dosing, active-controlled, 28-week safety extension study of the two pivotal 24
-week studies (PINNACLE 1 and 2). It was designed to evaluate the long-term
safety, tolerability, and efficacy of PT003 administered twice daily via pMDI
compared to PT001 and PT005 in patients with moderate to very severe COPD over a
total observation period of 52 weeks. Open-label tiotropium served as the active

About COPD
COPD is a progressive disease associated mainly with tobacco smoking, air
pollution or occupational exposure, which can cause obstruction of airflow in
the lungs resulting in debilitating bouts of breathlessness. It affects an
estimated 300 million people worldwide and is predicted to be the third leading
cause of death by 2020. Although COPD is widely regarded as a disease of the
elderly, 50 per cent of patients are estimated to be between 50 and 65 years of
age, meaning half of the COPD population is likely to be affected at a stage in
their life when they are at the peak of their earning potential and are likely
to have major family responsibilities.

About Pearl Therapeutics
Pearl Therapeutics is a wholly owned subsidiary of AstraZeneca, following its
acquisition in 2013 (http://www.astrazeneca.com/Media/Press
-releases/Article/20130610--az-acquire-pearl). The company is focused on
developing inhaled combination therapies for the treatment of highly prevalent
respiratory diseases, including COPD and asthma. Pearl Therapeutics' unique
porous particle co-suspension technology allows for the production of unique
fixed-dose combinations of different classes of drugs at different
concentrations in a single pressurised metered dose inhaler (pMDI) device. Fixed
-dose combination therapies can simplify treatment for patients, improving the
potential for convenience and compliance versus the use of separate inhalers.
Non-adherence is a well-documented issue in COPD and is associated with
detrimental effects on patient outcomes.

About AstraZeneca in Respiratory Disease
AstraZeneca has a long heritage in respiratory disease with 40 years of
experience and a strong franchise of marketed products. Our efforts to find
ground-breaking medicines and to develop new technologies are underpinned by a
deep understanding of the biology of respiratory diseases and our extensive
experience in primary care medicine.

Our strategy is to deliver a range of differentiated therapies, including novel
combinations, new devices, and innovative product offerings to treat respiratory
diseases, including asthma, chronic obstructive pulmonary disease (COPD) and
idiopathic pulmonary fibrosis (IPF). Our innovative precision approaches will
ensure the right treatment for the right patient.

AstraZeneca's respiratory portfolio includes asthma and COPD medicine Symbicort
and asthma medicine Pulmicort as well as COPD treatments, Eklira Genuair,
Tudorza Pressair and Duaklir Genuair.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com


Media Enquiries
Esra Erkal-Paler                       +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                      +44 20 7604 8037 (UK/Global)
Ayesha Bharmal                       +44 20 7604 8034 (UK/Global)
Jacob Lund                               +46 8 553 260 20 (Sweden)
Michele Meixell                         +1 302 885 6351 (US)

Investor Enquiries
Thomas Kudsk Larsen              +44 20 7604 8199         mob: +44 7818 524185
Karl Hård                                   +44 20 7604 8123      mob: +44 7789
Eugenia Litz                              +44 20 7604 8233         mob: +44 7884
Craig Marks                               +44 20 7 604 8591        mob: +44 7881
Christer Gruvris                         +44 20 7604 8126         mob: +44 7827

18 March 2015